| Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. | |
| | |
MedLine Citation:
|
PMID: 23045588 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up. PATIENTS AND METHODS: This report analyzes 4,760 patients with breast cancer randomly assigned to 5 years of monotherapy with letrozole or tamoxifen in the BIG 1-98 trial with available information on BMI at randomization. Multivariable Cox modeling assessed the association of BMI with disease-free survival, overall survival (OS), breast cancer-free interval, and distant recurrence-free interval and tested for treatment-by-BMI interaction. Median follow-up was 8.7 years. RESULTS: Seventeen percent of patients have died. Obese patients (BMI ≥ 30 kg/m(2)) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m(2)), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m(2)) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. CONCLUSION: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI. |
| | |
Authors:
|
Marianne Ewertz; Kathryn P Gray; Meredith M Regan; Bent Ejlertsen; Karen N Price; Beat Thürlimann; Hervé Bonnefoi; John F Forbes; Robert J Paridaens; Manuela Rabaglio; Richard D Gelber; Marco Colleoni; István Láng; Ian E Smith; Alan S Coates; Aron Goldhirsch; Henning T Mouridsen |
Related Documents
:
|
12385938 - Long-term survival after "drop metastases" of renal cell carcinoma to the bladder. 23076938 - Postoperative tamoxifen for ductal carcinoma in situ. 22977598 - Influence of a family history of breast and/or ovarian cancer on breast cancer outcomes. 23219378 - Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohor... 12735248 - Viegasella and mintera, two new genera of parmulariaceae (ascomycota), with notes on th... 17827048 - Owners 'perception of their cats' quality of life during cop chemotherapy for lymphoma. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-10-08 |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 30 ISSN: 1527-7755 ISO Abbreviation: J. Clin. Oncol. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-09 Completed Date: 2013-01-17 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 3967-75 Citation Subset: IM |
Affiliation:
|
Department of Oncology (ME), Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. mew@dadlnet.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents, Hormonal / therapeutic use* Aromatase Inhibitors / therapeutic use Body Mass Index* Breast Neoplasms / drug therapy*, mortality*, surgery Chemotherapy, Adjuvant Disease-Free Survival Estrogen Receptor Modulators / therapeutic use Female Follow-Up Studies Humans Kaplan-Meier Estimate Middle Aged Neoplasm Recurrence, Local / etiology* Nitriles / therapeutic use* Obesity / complications* Odds Ratio Predictive Value of Tests Prognosis Proportional Hazards Models Risk Assessment Risk Factors Tamoxifen / therapeutic use* Treatment Outcome Triazoles / therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
CA-75362/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Hormonal; 0/Aromatase Inhibitors; 0/Estrogen Receptor Modulators; 0/Nitriles; 0/Triazoles; 10540-29-1/Tamoxifen; 112809-51-5/letrozole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d...
Next Document: Validation of a Gene Expression Signature for Assessment of Lymph Node Metastasis in Oral Squamous C...